Investing $1.6 million into local community; set to employ over 40 people from the local area
HINESVILLE, Ga., April 29, 2019 — Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville, Georgia. The 11,000 square foot state-of-the-art facility officially opened its doors for business on April 29, 2019.
Ileana Carlisle, Biotest President, said “We look forward to being an active member of the Hinesville community. The opening of this plasma center is yet another step forward in our commitment to better serve the thousands of patients worldwide whose lives are enhanced through plasma-derived medicines”.
The total investment amounts to over $1.6 million in renovations of this newly constructed facility and expects to ultimately add over 40 jobs to the local economy. Currently, there are employment opportunities available for medical personnel and phlebotomists.
The new Biomat USA Plasma Center looks forward to providing the opportunity for area residents to donate plasma and being a committed member of the Hinesville community. Plasma donors contribute the much needed source material used in the production of plasma-derived medicines that can treat rare and life threatening medical conditions.
The Biotest plasma donor center is looking forward to joining the Grifols network of over 250 plasma donor centers and partnering with the Hinesville community to help meet Grifols daily mission of improving the health and wellbeing of people around the world.
To learn more about Grifols, this new Biotest plasma center, and the difference we make in the lives of patients and the healthcare community, please visit www.grifols.com and www.www.bloodplasma.com
Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.
Grifols’ three main divisions – Bioscience, Diagnostic and Hospital – develop, produce and market innovative products and services that are available in more than 100 countries.
With a network of 256 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.
Grifols is headquartered in Barcelona, Spain and has over 21,000 employees in 30 countries.
With nearly EUR 4,500 in revenues in 2018, Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.
The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ: GRFS). For more information, visit www.grifols.com